Aggressive Lymphomas
Conference Coverage
CAR T-cell studies dominate ongoing cellular therapy trials
Out of 753 cellular therapy trials listed at ClinicalTrials.gov as of March 30, 2018, 404 were CAR T therapy studies.
News
FDA lifts partial hold on tazemetostat trials
The U.S.
From the Journals
Outpatient lenalidomide/rituximab yields long-term MCL remission
Nearly two-thirds of evaluable patients with mantle cell lymphoma had durable responses to induction and maintenance.
News
FDA approves duvelisib for CLL/SLL and FL
The U.S.
News
Drug approved as part of frontline therapy for HL
The Japanese Ministry of Health, Labour and Welfare has approved brentuximab vedotin (Adcetris) in combination with doxorubicin, vinblastine, and...
Feature
NICE looks likely to reject use of Kymriah for DLBCL
The U.K. agency issued draft guidance recommending against use of tisagenlecleucel (Kymriah) a month after issuing similar guidance about...
News
CHMP supports new indication for venetoclax
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) approve a...
News
Stress linked to disease markers in CLL
New research has linked stress levels to markers of progressive disease in patients with chronic lymphocytic leukemia (CLL). Researchers found...
News
NICE rejects DLBCL indication for CAR T-cell therapy
The National Institute for Health and Care Excellence (NICE) has issued a draft guidance saying it cannot recommend tisagenlecleucel (Kymriah) as...
News
Guidelines for proton therapy in mediastinal lymphomas
Proton therapy can help mitigate toxicity in adults with mediastinal lymphomas, but the treatment should only be used in patients expected to...
News
Risks of watchful waiting in follicular lymphoma
A subset of follicular lymphoma (FL) patients managed with watchful waiting are vulnerable to organ dysfunction and transformation, according to...